F2 Vision SCS - Jan 11, 2022 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role: 10%+ Owner
Signature: F2 Vision SCS, /s/ Alain Renard
Stock symbol: CGEM
Transactions as of: Jan 11, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/13/2022, 04:22 PM
Next filing: May 16, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CGEM	Common Stock	Other		-1.19M	-40.78%		1.72M	Jan 11, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 11, 2022, F2 Vision SCS ("F2 Vision") distributed, for no consideration, 1,187,734 shares of Common Stock of the Issuer (the "Shares") to certain of its limited partners representing such limited partner's pro rata interest in the shares held by F2 Vision. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F2	These securities are owned directly by F2 Vision. F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Content

On January 11, 2022, F2 Vision SCS ("F2 Vision") distributed, for no consideration, 1,187,734 shares of Common Stock of the Issuer (the "Shares") to certain of its limited partners representing such limited partner's pro rata interest in the shares held by F2 Vision. The aforementioned distribution was made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

These securities are owned directly by F2 Vision. F2 Vision Management Sarl ("F2 Vision Management") is the appointed manager of F2 Vision. Morana Jovan-Embiricos is the founding director of F2 Vision Management and has the sole power to vote upon the acquisition, holding and disposal of all shares held by F2 Vision. Dr. Jovan-Embiricos disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.